Priscilla Pereira

Priscilla Pereira

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2017 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
KLKELY LIMA
KELY LIMA
RGRafaelli de Souza Gomes
Rafaelli de Souza Gomes
PPPriscilla Pereira
Priscilla Pereira
PCPaula Giselle Czaikoski
Paula Giselle Czaikoski
CRCarolina Ribeiro
Carolina Ribeiro
MMMarta Monteiro
Marta Monteiro
Macrophages and neutrophils are key components involved in the regulation of numerous chronic inflammatory diseases, infectious disorders, and especially certain autoimmune disease. However, little is known regarding the contribution of these cells to the pathogenesis of autoimmune disorders. Recent studies have aimed to clarify certain important factors affecting the immunogenicity of these cells, including the type and dose of antigen, the microenvironment of the cell-antigen encounter, and the number, subset, and phenotype of these cells, which can prevent or induce autoimmune responses. This review highlights the role of macrophage subsets and neutrophils in injured tissues, supporting their cooperation during the pathogenesis of certain autoimmune diseases.

13 January 2011 in Fibrogenesis & Tissue Repair
Verified
Journal Article
Open access
PDF file
CBClaudia S Bitencourt
Claudia S Bitencourt
PPPriscilla Pereira
Priscilla Pereira
SRSimone G. Ramos
Simone G. Ramos
Suely Vilela SampaioSuely Vilela Sampaio
Suely Vilela Sampaio
Eliane Candiani ArantesEliane Candiani Arantes
Eliane Candiani Arantes
LFLúcia H. Faccioli
Lúcia H. Faccioli
Hyaluronidases (HYALs) comprise a group of enzymes that degrade hyaluronic acid (HA). In this report, we reveal that a single intranasal inoculation of HYAL induces an increase in mononuclear cells within the bronchoalveolar space demonstrating a mesenchymal-like phenotype, expressing stem cell antigen-1 (SCA-1), CD44 and CD73 but not CD34, CD45, CD3, CD4, CD8 or CD19. This influx of mesenchymal stem cell (MSC)-like cells was dependent on leukotriene production within the lung parenchyma. These findings prompted experiments demonstrating that HYAL treatment potently blocked bleomycin-induced lung injury and fibrosis while decreasing transforming growth factor (TGF)-β production and collagen deposition. These data suggest that HYAL is a novel and promising tool to use autologous MSC-like cells in the treatment of pulmonary fibrosis.